GLP-1 drug shortages, driven by cosmetic and weight loss purposes, result in access disparities among individuals with ...

New data shows that government-funded health insurance plans in the United States provide the majority of coverage for ...

In October, the FDA removed Mounjaro and Zepbound—the diabetes and obesity GLP-1 drugs made by Eli Lilly—from the shortage ...

Patients who would benefit from a GLP-1 face significant challenges when it comes to access. Shortages have made it difficult ...

With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...

U.S. government health plans account for the lion's share of coverage for popular new weight-loss drugs, far beyond the ...

Pharmacies that make customized medications are asking the federal Food and Drug Administration to protect their right to ...

Nov. 6, 2024 – The FDA has updated the labels for all GLP-1 weight loss drugs with a warning about pulmonary aspiration ...

The FDA updated GLP-1 drug labels to warn of the risk of patients breathing food into their lungs while under anesthesia for ...

Research shows that 1 in 8 adults in the US has used one of the popular GLP-1 medications, most of them trying to manage ...